Filing
1st Quarter - Report
Lobbying activity
4
BLOCKING Act, Patent Thickets, Patent Settlements, Interchangeability of biosimilars, Q1Q2 transparency, PBM Reform, Inflation Reduction Act, Abbreviated Drug Labeling, Tariffs, Domestic Manufacturing, DSCSA.
Reimbursement of generic pharmaceuticals and biosimilars.
Country of Origin labeling.
Incentivizing domestic manufacturing of essential medicines.